Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2024
Reporting Period: Third Quarter 2024 (Three and nine months ended September 30, 2024)
This filing announces the issuance of an unaudited earnings press release regarding the Company's results of operations and financial position. The report includes both GAAP and non-GAAP financial measures.
Key Financial Metrics
Note: The provided text describes the methodology for financial reporting but does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release (Exhibit 99.1) for specific figures.
- Non-GAAP Measures Reported: Earnings per share, operating income, operating margin, tax rate, and operating expenses (including cost of sales, R&D, and SG&A).
- Free Cash Flow (FCF): Defined as operating cash flow minus capital expenditures (GAAP basis).
- Debt Instruments: The filing lists 2.000% Senior Notes due 2026 (Symbol: AMGN26) as registered securities.
Material Changes and Adjustments
The filing details specific items excluded from GAAP results to calculate non-GAAP measures, which may impact period-over-period comparisons:
- Acquisition-Related Expenses: Excludes amortization of intangible assets (e.g., developed-product-technology rights, licensing rights) and step-up to fair value of acquired inventory. Also excludes net impairment charges of in-process R&D assets.
- Restructuring and Cost Savings: Excludes facility charges (asset impairments, accelerated depreciation) and severance/benefits related to transformation efforts.
- Other Items: Excludes gains/losses on equity securities, legal settlement items, and specific interest/fees related to the Horizon Therapeutics acquisition (March 2023 senior notes and bridge credit agreement costs).
Guidance, Outlook, and Management Commentary
Management Usage: Management utilizes non-GAAP measures for internal budgeting, financial planning, resource allocation, and evaluating performance against incentive compensation targets. The Company believes these measures facilitate comparisons of ongoing business operations across periods.
Legal Disclaimer: The information in this Item 2.02 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless specifically stated.
Guidance: The provided text does not contain specific forward-looking guidance or numerical outlooks for future periods.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical values for Q3 2024 revenue, net income, and EPS, as they are not present in this 8-K summary text.
- Verify the reconciliation tables in the press release to understand the magnitude of adjustments between GAAP and non-GAAP results.
- Confirm the impact of the Horizon Therapeutics acquisition on current debt issuance costs and interest expense.
- Check for any updates on legal proceedings or settlements mentioned as "other items" in the non-GAAP adjustments.